Investigational Drug Study for Patients Diagnosed with Non-Alcoholic Steatohepatitis (NASH) and Compensated Cirrhosis

Clinical Trial Title

A Randomized Placebo-Controlled Phase 3 Study to Evaluate the Effect of an Investigational Drug on Liver-Related Outcomes in Patients with Well-Compensated Non-Alcoholic Steatohepatitis (NASH) and Cirrhosis

National Clinical Trial Number:

NCT05500222

Contact Information

Grace Lin

Call (312) 563-2141

Send Email

Clinical Trial Protocol Description:

This study is designed to assess an investigational drug vs placebo in the treatment of NASH cirrhosis. Patients must be willing to travel to Rush's downtown campus for regular research visits. This study does not require liver biopsies.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

Have been diagnosed with non-alcoholic steatohepatitis (NASH) and cirrhosis.

You will be excluded from the study if any of the following criteria apply to you:

Have active hyperthyroidism or untreated clinical hypothyroidism.
Have active autoimmune disease, including actively treated lupus, rheumatoid arthritis, inflammatory bowel disease, or autoimmune hepatitis.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.